Lifestyle plus pharmacotherapy targeting blood pressure lowering preferably with Renin-angiotensin-aldosterone system inhibitor, lipid lowering, and antidiabetic agents including Sodium-glucose Cotransporter-2 inhibitors, glucagon-like peptide 1 agonists, as well as non-steroidal mineralocorticoids optimize CVD and kidney risk reduction in patients with diabetes and CKD [29, 31]. This evidence concerns the gene SLC5A2 and chronic kidney disease.